PRESS RELEASE

PRESS RELEASE

Jul 20, 2018

Antengene Corporation’s Strategic Partner, Karyopharm Therapeutics, Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients

Shanghai, China and NEWTON, Mass. – July 18, 2018 – Antengene Corporation’s Strategic Partner, Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a cli...

May 24, 2018

Antengene and Karyopharm Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia

SHANGHAI, China and NEWTON, Mass. – May 24, 2018 – Antengene Corporation (Antengene) and Karyopharm Therapeutics Inc. (Nasdaq:KPTI) (Karyopharm), ...

May 15, 2018

Dr. Yijun Yang and Dr. Bo Shan joined Antengene Corporation

Antengene Co., Ltd. announced on May 15, 2018 that Dr. Yijun Yang and Dr. Bo Shan joined Antengene as Vice President. Dr. Yijun will be responsible fo...

Mar 26, 2018

Antengene Corporation Announces TFDA Approval of IND Application for a Phase II Study of ATG-008, a Next Generation mTOR Inhibitor, in Patients with Late-stage Hepatocellular Carcinoma (HCC)

On March 26, 2018, Antengene Corporation, a China-based biopharmaceutical company that focuses on introducing cutting-edge treatments to China and oth...

Feb 11, 2018

Antengene Corporation has submitted The Phase 2 Clinical Trial Application of ATG-008 to China, Taiwan and Korea

BEIJING, CHINA, February 7,–Antengene Corporation has submitted The Phase 2 Clinical Trial Application of ATG-008 to China, Taiwan and Korea. ...

Nov 30, 2017

Antengene Corporation attended Drug Development Case Study Workshop held by CFDA

BEIJING, CHINA, November 30, 2017–Dr. Jay Mei, founder of Antengene Corporation attended Drug Development Case Study Workshop with the CFDA in B...

Sep 28, 2017

Antengene Corporation Attend the 20th Annual CSCO Meeting

XIAMEN, CHINA, September 28, 2017 – The 20th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) was held at Xiamen International Conferen...

Sep 15, 2017

Antengene Corporation Attend Qiming Venture Partners CEO Summit

CHENGDU, CHINA, September 15, 2017 – The 2017 Qiming Venture Partners CEO Summit successfully took place in Chengdu, China. Dr. Jay Mei, CEO and f...

Aug 16, 2017

Antengene Corporation Secures $21M in Series A Financing Round Led by Qiming Venture Partners

SHANGHAI, CHINA, August 16, 2017 – Antengene Corporation, a clinical stage biopharmaceutical company, announced today the completion of its Series A...

Apr 20, 2017

Antengene announces China manufacturing plant in Shaoxing, China

SHAOXING, CHINA, April 20, 2017 – Today, Antengene Corporation inaugurated its commercial manufacturing site for biopharmaceuticals in Binhai Indust...

Apr 13, 2017

Celgene and Antengene Corporation Announced Long-term Collaboration and Celgene has Become Shareholder of Antengene

SHAOXING, CHINA, April 13, 2017 – Antengene Corporation, a clinical stage biopharmaceutical company, announced strategic partnership with Celgene (N...